# China Metabolomics Services Market

> China Metabolomics Services Market Research Report By Product Type (Chromatography, Metabolomics Bioinformatics Services, Mass Spectrometry) and By Application (Biomedical and Pharmaceutical, Agriculture, Food) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.69%
- **2024:** $ 28.13 Million
- **2025:** $ 30.29 Million
- **2035:** $ 63.52 Million
- **Key Players:** Metabolon Inc (US), Biocrates Life Sciences AG (AT), Agilent Technologies Inc (US), Thermo Fisher Scientific Inc (US), Waters Corporation (US), PerkinElmer Inc (US), Sierra Analytics Inc (US), Creative Proteomics (US)

**Report ID:** MRFR/HS/47910-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-metabolomics-services-market-49664

---

## Market Summary

## **China Metabolomics Services Market Overview**

As per MRFR analysis, the China Metabolomics Services Market Size was estimated at 163.75 (USD Million) in 2023. The China Metabolomics Services Market Industry is expected to grow from 183.75(USD Million) in 2024 to 1,150 (USD Million) by 2035. The China Metabolomics Services Market CAGR (growth rate) is expected to be around 18.143% during the forecast period (2025 - 2035)

**Key China Metabolomics Services Market Trends Highlighted**

The China Metabolomics Services Market is experiencing significant advancements driven by increasing investment in healthcare research and development. With the nation focusing on strengthening its biotechnology sector, the government's priority on enhancing healthcare services and personalized medicine is propelling demand for metabolomics. The integration of metabolomics with genomics and proteomics is becoming essential for various sectors, including pharmaceuticals, agriculture, and environmental monitoring, further driving market growth. 

Moreover, the trend toward personalized healthcare in China is creating opportunities for metabolomics services.The rising prevalence of chronic diseases and an aging population leads to a greater focus on precision medicine, which relies heavily on metabolomic profiling. Chinese research institutions and universities are increasingly adopting these services to propel innovative drug discovery and diagnostics, thus expanding the capabilities of the market. Recent trends indicate a surge in collaborations among biotechnology companies, research organizations, and academic institutions, which enhance technological advancements within the metabolomics field. 

These partnerships are essential in establishing a comprehensive metabolomics infrastructure, thereby addressing the growing need for effective drug development and diagnostics.Furthermore, the increasing utilization of artificial intelligence and machine learning in metabolomics data analysis is facilitating improved insights and data interpretation, leading to better healthcare outcomes. China's proactively supportive regulatory environment aims to accelerate the pace of innovation in life sciences. 

This creates a favorable atmosphere for the growth of metabolomics services. As the country continues to emphasize sustainability and health, the market holds the promise of significant growth through the exploration of new applications and technologies in metabolomics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Metabolomics Services Market Drivers**

**Increasing Focus on Personalized Medicine**

The China Metabolomics Services Market Industry is expanding as a result of the country's need for tailored medication. A concentrated attempt has been made to customize treatment regimens to each patient's unique profile due to the rising prevalence of chronic illnesses. For instance, the demand for targeted therapeutics is influenced by the National Health Commission of China's projection that the number of diabetes patients has significantly increased, surpassing 140 million in 2022. 

Prominent biopharmaceutical firms, like WuXi AppTec and Shanghai Fosun Pharmaceutical, are making significant investments in metabolomic technology in order to create individualized treatment plans. The focus on precision medicine is a key factor in the growth of this industry as it closely matches the potential of metabolomics.

**Rapid Advancements in Technology**

The evolution of high-throughput technologies in the field of metabolomics is enhancing the capabilities of the China Metabolomics Services Market Industry. Innovations in analytical methods such as mass spectrometry and nuclear magnetic resonance are significantly streamlining metabolic profiling processes. According to China's Ministry of Science and Technology, over 1,000 patents related to metabolomics technologies were filed in the last five years, highlighting the research activities within the region.

Companies like BGI Genomics and Beijing Genomics Institute are at the forefront of these technological advancements, allowing for more precise and faster analysis, which is crucial for research and clinical applications. This technological surge promises not only to improve service delivery but also to expand the overall market.

**Growing Investment in Research and Development**

There is a notable increase in investment in Research and Development (R&D) for metabolomics in China, driven by both government initiatives and private sector involvement. The Chinese government has committed to doubling its annual spending on life sciences research aimed at accelerating innovation within the healthcare sector, which includes metabolomics. 

As per the National Natural Science Foundation of China, research funding has reached over 1 billion USD dedicated to biomedical projects in recent years.This policy shift encourages organizations such as Novogene and Huadong Medicine to invest significantly in metabolomic services, fostering growth and expanding service offerings within the China Metabolomics Services Market Industry.

**Rising Incidence of Metabolic Disorders**

The increasing prevalence of metabolic disorders, such as obesity and diabetes, represents a critical driver for the China Metabolomics Services Market Industry. Statistics from the Chinese Center for Disease Control and Prevention indicate that nearly 50% of adults are now overweight, with over 30% classified as obese. 

This alarming trend necessitates improved diagnostic tools and preventive measures, thus fueling the demand for metabolomics services.Organizations like the Chinese Diabetes Society are advocating for enhanced metabolic profiling to understand these conditions better. As the focus on metabolic health intensifies, companies involved in metabolomics are poised for significant growth, catering to the urgent need for better diagnostic and therapeutic solutions.

**China Metabolomics Services Market Segment Insights**

**Metabolomics Services Market Product Type Insights**

The China Metabolomics Services Market demonstrates significant growth potential and diversification driven by various product types integral to the advancement of metabolomics research and applications. Among different product types, Chromatography stands out as a pivotal technique, widely adopted for the separation and analysis of metabolites. This method is crucial for ensuring the accuracy and reliability of metabolomics studies, thereby facilitating advancements in areas such as biomarker discovery and personalized medicine. 

Driven by the increasing demand for precise analytical techniques, the emphasis on Chromatography in the country continues to grow, as it forms the backbone of numerous research and clinical applications. Metabolomics Bioinformatics Services also play a critical role in the market, providing essential support in the interpretation and analysis of vast amounts of data generated through metabolomics studies. Given China's rapid expansion in the life sciences sector, these bioinformatics services are becoming increasingly significant.

The ability to harness computational tools to extract meaningful insights from complex datasets aids researchers in understanding metabolic pathways, which is essential for drug development and metabolic profiling. 

Moreover, the rising adoption of artificial intelligence in bioinformatics is poised to enhance the efficiency and accuracy of data analysis, thereby further boosting the demand for these services within the China Metabolomics Services Market.Mass Spectrometry is another vital product type that significantly contributes to the landscape of metabolomics. Renowned for its precision and high sensitivity in detecting and quantifying metabolites, Mass Spectrometry finds extensive application in both academic research and clinical diagnostics. 

As the need for advanced analytical capabilities continues to rise in China, particularly in the areas of drug analysis and food safety testing, Mass Spectrometry is likely to maintain a dominating position. The integration of innovative technologies in mass spectrometric methods, such as the development of high-resolution mass spectrometers, is expected to fuel further advancements in metabolomics services, ensuring the country remains at the forefront of this scientific discipline.

Overall, the product type segmentation in the China Metabolomics Services Market reflects a concerted focus on improving analytical techniques and data interpretation capabilities, which is vital for addressing the complexities of metabolic research. 

Growth in the metabolomics field is driven by an expanding need for detailed metabolic profiling across various sectors, including pharmaceuticals, nutraceuticals, and clinical diagnostics, with each product type playing a crucial role in achieving comprehensive metabolite analysis and biomarker discovery. The landscape for metabolomics services continuously evolves in China, with significant investments and innovations contributing to sustained momentum and opportunities in the market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Metabolomics Services Market Application Insights**

The China Metabolomics Services Market is characterized by diverse applications, significantly impacting sectors like Biomedical and Pharmaceutical, Agriculture, and Food. The Biomedical and Pharmaceutical segment plays a crucial role in drug development and personalized medicine, providing essential insights into metabolic profiles that aid in understanding disease mechanisms and tailoring treatments. Agriculture applications are increasingly leveraging metabolomics to enhance crop yields and improve food quality, aligning with China's focus on food security and sustainable agricultural practices.

In the Food industry, metabolomics is vital for analyzing nutritional content and flavor profiles, which aligns with the growing consumer demand for health-oriented products. With rapid advancements in technology and increasing awareness of metabolomics benefits, these segments serve as a driving force in the China Metabolomics Services Market, contributing to research and development activities and fostering innovation in various industries. The integration of metabolomics into these sectors not only supports economic growth but also addresses societal needs, showcasing its importance in China's strategic vision for development and sustainability.

**China Metabolomics Services Market Key Players and Competitive Insights**

The China Metabolomics Services Market is experiencing significant growth driven by advancements in analytical technologies and increasing demand for comprehensive metabolic profiling in various research disciplines, including pharmaceuticals, clinical diagnostics, and agricultural studies. Companies operating in this market are leveraging sophisticated mass spectrometry and nuclear magnetic resonance techniques to offer a wide range of services, catering to different sectors that require detailed metabolite analysis. The competitive landscape is characterized by several key players that focus on enhancing their service portfolios while fostering partnerships and collaborations to expand market access and improve research capabilities. 

The growing emphasis on personalized medicine and the application of metabolomics in biomarker discovery are additional factors influencing competitiveness as businesses strive to differentiate their offerings in a rapidly evolving environment.Danaher Corporation has established a strong presence in the China Metabolomics Services Market by leveraging its expertise in life sciences and analytical instrumentation. The company is recognized for its advanced technologies in biochemical analysis and has built a reputation for providing reliable and cutting-edge metabolomics solutions tailored to meet local market needs.

With a commitment to innovation and quality, Danaher’s strengths lie in its robust product range, including instruments and systems designed for high-throughput screening and metabolic analysis. 

The company’s ability to adapt to regional demands, combined with a network of local partnerships, allows it to effectively serve academic institutions, research organizations, and the biopharmaceutical industry in China, thus solidifying its competitive edge in this dynamic marketplace.Illumina is another significant player in the China Metabolomics Services Market, known primarily for its next-generation sequencing technology that complements its metabolomics offerings. 

The company's involvement in the metabolomics space is enhanced by its portfolio of key products and services that support large-scale genomic and transcriptomic studies, which are essential for comprehensive metabolic profiling. Illumina's strengths include state-of-the-art sequencing platforms and significant R&D investments aimed at integrating metabolomics with genomics for deeper biological insights. 

Its market presence in China has been bolstered by strategic partnerships and collaborations with local research institutes, which enhance its accessibility and relevance. Furthermore, Illumina's focus on innovative solutions and its intent to expand through mergers and acquisitions add competitive vigor, reflecting a commitment to advancing the metabolomics field in China and delivering solutions that address the distinct needs of the regional market.

**Key Companies in the China Metabolomics Services Market Include**

**China Metabolomics Services Market Industry Developments**

The China Metabolomics Services Market has experienced significant developments recently. In September 2023, Danaher Corporation announced intentions to expand its portfolio in metabolomics by integrating cutting-edge technologies to enhance analysis speed and accuracy, addressing the growing demand for precision medicine in China. Illumina is also scaling its operations by collaborating with local Chinese research institutions to leverage metabolomics for personalized healthcare solutions. ChromaDex has focused on synergistic partnerships with academic institutions for metabolomics research, showcasing its commitment to innovation in the region. 

Recently, Merck KGaA expanded its services in China, announcing an investment in metabolomics research facilities aimed at catering to the local biotechnology sector. Over the past two to three years, companies like PerkinElmer and BioRad Laboratories have noted growth in market valuation by developing new metabolomics technologies. The collective growth of these companies indicates a robust future for the metabolomics sector in China, driven by advancements in research and development efforts and an increasing emphasis on personalized medicine, evidenced by rising government investments in biotechnology.

**China Metabolomics Services Market Segmentation Insights**

## Market Drivers

### Growing Research Investments

The metabolomics services market in China is experiencing a surge in research investments, particularly from both public and private sectors. The Chinese government has been actively promoting research and development in life sciences, allocating substantial funding to various initiatives. In 2023, research funding in the life sciences sector reached approximately $10 billion, with a significant portion directed towards metabolomics. This influx of capital is likely to enhance the capabilities of service providers, enabling them to offer more advanced and comprehensive analyses. As a result, the market is expected to expand, driven by the increasing number of research projects and collaborations between academic institutions and industry players. This trend indicates a robust growth trajectory for the metabolomics services market, as more entities seek to leverage metabolomic data for innovative applications.

### Expansion of Biopharmaceutical Sector

The biopharmaceutical sector in China is rapidly expanding, which is significantly impacting the metabolomics services market. As the country aims to become a leader in biopharmaceutical innovation, there is an increasing reliance on metabolomics for drug discovery and development. In 2025, the biopharmaceutical market in China is projected to reach $200 billion, with a substantial portion of this growth attributed to the integration of metabolomic technologies. This integration allows for a more comprehensive understanding of drug interactions and metabolic pathways, ultimately leading to more effective therapies. Consequently, the demand for metabolomics services is expected to rise, as biopharmaceutical companies seek to enhance their research capabilities and streamline the drug development process. The metabolomics services market is thus likely to benefit from this burgeoning sector.

### Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases in China drives the metabolomics services market. With conditions such as diabetes, cardiovascular diseases, and cancer on the rise, there is a growing need for effective diagnostic and therapeutic strategies. Metabolomics offers valuable insights into disease mechanisms and potential biomarkers, facilitating early detection and personalized treatment approaches. According to recent statistics, chronic diseases account for over 80% of total healthcare expenditures in China, highlighting the urgent need for innovative solutions. This demand for metabolomic analyses is likely to propel the market forward, as healthcare providers and researchers seek to utilize metabolomics for better disease management and prevention strategies. The metabolomics services market is thus positioned to play a pivotal role in addressing the healthcare challenges posed by chronic diseases.

### Increased Focus on Nutritional Research

There is a notable increase in the focus on nutritional research within China, which is driving the metabolomics services market. As public awareness of health and nutrition grows, researchers are increasingly investigating the relationship between diet, metabolism, and health outcomes. This trend is reflected in the rising number of studies exploring the metabolic effects of various dietary components. In 2023, funding for nutritional Market Research Future reached approximately $1.5 billion, indicating a strong commitment to understanding the role of nutrition in health. Metabolomics provides essential tools for analyzing metabolic changes in response to dietary interventions, making it a valuable asset for researchers in this field. As a result, the metabolomics services market is likely to see increased demand from academic institutions and food industry stakeholders seeking to leverage metabolomic insights for product development and health promotion.

### Advancements in Data Analysis Technologies

The metabolomics services market is being propelled by advancements in data analysis technologies, which are enhancing the capabilities of metabolomic studies. In recent years, there has been a significant evolution in bioinformatics tools and software, enabling researchers to process and interpret complex metabolomic data more efficiently. These advancements are crucial, as the volume of data generated from metabolomic analyses can be overwhelming. In 2025, it is estimated that the market for bioinformatics solutions in China will exceed $5 billion, reflecting the growing importance of data analysis in the life sciences. As service providers adopt these cutting-edge technologies, they can offer more accurate and reliable results, thereby attracting a broader client base. This trend suggests that the metabolomics services market will continue to grow, driven by the need for sophisticated data analysis in research and clinical applications.

## Future Outlook

The [Metabolomics Services Market](https://www.marketresearchfuture.com/reports/metabolomics-services-market-8435) in China is projected to grow at a 7.69% CAGR from 2025 to 2035, driven by advancements in technology and increasing demand for personalized medicine.

**New opportunities:**

- Development of integrated metabolomics platforms for clinical diagnostics.
- Expansion of metabolomics applications in agricultural biotechnology.
- Partnerships with pharmaceutical companies for drug discovery and development.

By 2035, the metabolomics services market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product and Service: Chromatography (Largest) vs. Mass Spectrometry (Fastest-Growing)

In the China metabolomics services market, Chromatography holds the largest market share, showcasing its importance in separating and analyzing complex biological samples. While Chromatography dominates, Mass Spectrometry is rapidly gaining traction and is expected to expand its share significantly due to its precision and efficiency in metabolite analysis.

Growth in the segment is driven by increasing adoption of advanced analytics in healthcare and pharmaceuticals. Innovations in technology, coupled with a rising need for personalized medicine and early disease detection, are propelling the demand for both Chromatography and Mass Spectrometry services. The focus on enhanced bioinformatics is also supporting market expansion, indicating a healthy growth trajectory for these technologies.

Chromatography (Dominant) vs. Metabolomics Bioinformatics Services (Emerging)

Chromatography remains the dominant force in the China metabolomics services market, favored for its reliability in analyzing complex mixtures and high throughput. With a wide range of applications, it serves various industries including healthcare and food safety. Meanwhile, Metabolomics Bioinformatics Services are emerging as crucial in interpreting large datasets generated by metabolomics studies. This segment is characterized by rapid technological advancements, as well as an increasing emphasis on data analysis competencies, making it an attractive area for investment and research. As the market evolves, integration between these two segments is anticipated, enhancing overall research capabilities in metabolomics.

### By Application: Biomedical and Pharmaceutical (Largest) vs. Food (Fastest-Growing)

The market for application segments indicates that the Biomedical and Pharmaceutical sector holds a dominant market share. This prevalence can be attributed to the increasing investments in drug development, personalized medicine, and comprehensive biomarker discovery. The growth in this sector is heavily influenced by the rising demand for precision healthcare, propelling the need for advanced metabolomic analyses.

Conversely, the Food sector is emerging as the fastest-growing segment, driven by heightened consumer awareness of food quality and safety. With growing interest in nutritional genomics and food innovation, the demand for metabolomics in food testing and development is expanding rapidly. This trend reflects an increasing focus on health and wellness, which influences dietary choices and food production strategies.

Biomedical and Pharmaceutical (Dominant) vs. Food (Emerging)

The Biomedical and Pharmaceutical segment in the China metabolomics services market is characterized by its substantial influence driven by ongoing advancements in healthcare technologies, particularly in drug discovery and development. This sector is robust, supported by extensive research initiatives and clinical applications that seek to unveil complex biological processes. On the other hand, the Food segment is emerging, reflecting growing consumer demands for quality, safety, and nutraceutical products. This segment leverages metabolomic sciences to improve food quality, developing novel products that cater to health-centric consumer trends. While the Biomedical and Pharmaceutical segment remains dominant, the Food sector is steadily gaining traction, demonstrating innovative applications and significant growth potential.

## Competitive Benchmarking

The metabolomics services market in China is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for personalized medicine. Key players such as Metabolon Inc (US), Agilent Technologies Inc (US), and Thermo Fisher Scientific Inc (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market presence. Metabolon Inc (US) focuses on expanding its service offerings through collaborations with academic institutions, which appears to bolster its research capabilities and market reach. Meanwhile, Agilent Technologies Inc (US) emphasizes digital transformation, integrating advanced data analytics into its metabolomics services, thereby enhancing the precision and efficiency of its offerings. These strategies collectively contribute to a competitive environment that is increasingly focused on technological advancement and customer-centric solutions.
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to better serve the Chinese market. The competitive structure of the market is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse service offerings, yet the influence of major players like Thermo Fisher Scientific Inc (US) and Waters Corporation (US) is substantial, as they set industry standards and drive innovation.
In October 2025, Thermo Fisher Scientific Inc (US) announced the launch of a new suite of metabolomics analysis tools designed to enhance the accuracy of biomarker discovery. This strategic move is significant as it positions the company to capture a larger share of the growing demand for precision medicine in China, where the focus on personalized healthcare is intensifying. The introduction of these tools is likely to strengthen Thermo Fisher's competitive edge by providing researchers with more robust analytical capabilities.
In September 2025, Waters Corporation (US) expanded its partnership with local Chinese biotech firms to enhance its metabolomics service offerings. This collaboration is crucial as it allows Waters to tap into local expertise and accelerate the development of tailored solutions for the Chinese market. Such strategic alliances not only enhance Waters' service portfolio but also facilitate quicker responses to market needs, thereby improving customer satisfaction and loyalty.
In August 2025, Metabolon Inc (US) secured a significant funding round aimed at expanding its metabolomics platform capabilities. This investment is indicative of the company's commitment to innovation and suggests a proactive approach to scaling its operations in China. By enhancing its platform, Metabolon is likely to improve its competitive positioning, particularly in the rapidly evolving landscape of metabolomics research.
As of November 2025, current trends in the metabolomics services market include a pronounced shift towards digitalization and AI integration, which are reshaping competitive dynamics. Companies are increasingly forming strategic alliances to leverage complementary strengths, thereby enhancing their service offerings and market reach. The competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the diverse needs of the market.

## Recent News & Developments

The China Metabolomics Services Market has experienced significant developments recently. In September 2023, Danaher Corporation announced intentions to expand its portfolio in metabolomics by integrating cutting-edge technologies to enhance analysis speed and accuracy, addressing the growing demand for precision medicine in China. Illumina is also scaling its operations by collaborating with local Chinese research institutions to leverage metabolomics for personalized healthcare solutions. ChromaDex has focused on synergistic partnerships with academic institutions for metabolomics research, showcasing its commitment to innovation in the region. 

Recently, Merck KGaA expanded its services in China, announcing an investment in metabolomics research facilities aimed at catering to the local biotechnology sector. Over the past two to three years, companies like PerkinElmer and BioRad Laboratories have noted growth in market valuation by developing new metabolomics technologies. The collective growth of these companies indicates a robust future for the metabolomics sector in China, driven by advancements in research and development efforts and an increasing emphasis on personalized medicine, evidenced by rising government investments in biotechnology.

## Report Scope

| MARKET SIZE 2024 | 28.13(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 30.29(USD Million) |
| MARKET SIZE 2035 | 63.52(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.69% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Metabolon Inc (US), Biocrates Life Sciences AG (AT), Agilent Technologies Inc (US), Thermo Fisher Scientific Inc (US), Waters Corporation (US), PerkinElmer Inc (US), Sierra Analytics Inc (US), Creative Proteomics (US) |
| Segments Covered | Product and Service, Application |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative metabolomics services solutions. |
| Key Market Dynamics | Rising demand for personalized medicine drives growth in metabolomics services, influenced by regulatory advancements and technological innovations. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the market valuation of the China metabolomics services market in 2024?**
A: The market valuation was $28.13 Million in 2024.

**Q: What is the projected market valuation for the China metabolomics services market by 2035?**
A: The projected valuation for 2035 is $63.52 Million.

**Q: What is the expected CAGR for the China metabolomics services market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.69% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the China metabolomics services market?**
A: Key players include Metabolon Inc, Biocrates Life Sciences AG, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Waters Corporation, PerkinElmer Inc, Sierra Analytics Inc, and Creative Proteomics.

**Q: What were the revenue figures for chromatography services in 2024?**
A: Chromatography services generated $8.43 Million in 2024.

**Q: How much revenue is projected for metabolomics bioinformatics services by 2035?**
A: Metabolomics bioinformatics services are projected to reach $21.12 Million by 2035.

**Q: What was the revenue for mass spectrometry services in 2024?**
A: Mass spectrometry services generated $10.45 Million in 2024.

**Q: Which application segment had the highest revenue in 2024?**
A: The biomedical and pharmaceutical application segment had the highest revenue at $10.0 Million in 2024.

**Q: What is the projected revenue for the agriculture application segment by 2035?**
A: The agriculture application segment is projected to reach $18.0 Million by 2035.

**Q: What revenue growth is expected for the food application segment during the forecast period?**
A: The food application segment is expected to grow from $10.13 Million in 2024 to $22.52 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-metabolomics-services-market-49664*